» Articles » PMID: 39296083

Natural Products for the Treatment of Hypertrophic Scars: Preclinical and Clinical Studies

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Sep 19
PMID 39296083
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertrophic scarring (HS) is a complication of wound healing that causes physiological and psychological distress in patients. However, the possible mechanism underlying HS is not fully understood, and there is no gold standard for its treatment. Natural products are more effective, economical, convenient, and safe than existing drugs, and they have a wide application prospect. However, there is a lack of literature on this topic, so we reviewed in vivo, in vitro, and clinical studies and screened natural products showing beneficial effects on HS that can become potential therapeutic agents for HS to fill in the gaps in the field. In addition, we discussed the drug delivery systems related to these natural products and their mechanisms in the treatment of HS. Generally speaking, natural products inhibit inflammation, myofibroblast activation, angiogenesis, and collagen accumulation by targeting interleukins, tumor necrosis factor-α, vascular endothelial growth factors, platelet-derived growth factors, and matrix metalloproteinases, so as to play an anti-HS effects of natural products are attributed to their anti-inflammatory, anti-proliferative, anti-angiogenesis, and pro-apoptotic (enhancing apoptosis and autophagy) roles, thus treating HS. We also screened the potential therapeutic targets of these natural compounds for HS through network pharmacology and constructed a protein-protein interaction (PPI) network, which may provide clues for the pharmacological mechanism of natural products in treating this disease and the development and application of drugs.

Citing Articles

Epigallocatechin-3-gallate therapeutic potential in human diseases: molecular mechanisms and clinical studies.

Alam M, Gulzar M, Akhtar M, Rashid S, Zulfareen , Tanuja Mol Biomed. 2024; 5(1):73.

PMID: 39725830 PMC: 11671467. DOI: 10.1186/s43556-024-00240-9.

References
1.
Li B, Gao C, Diao J, Wang D, Chu F, Li Y . Aberrant Notch signalling contributes to hypertrophic scar formation by modulating the phenotype of keratinocytes. Exp Dermatol. 2015; 25(2):137-42. DOI: 10.1111/exd.12897. View

2.
Shan S, Zhang Y, Wu M, Yi B, Wang J, Li Q . Naringenin attenuates fibroblast activation and inflammatory response in a mechanical stretch-induced hypertrophic scar mouse model. Mol Med Rep. 2017; 16(4):4643-4649. PMC: 5647020. DOI: 10.3892/mmr.2017.7209. View

3.
Oosterwijk A, Mouton L, Schouten H, Disseldorp L, van der Schans C, Nieuwenhuis M . Prevalence of scar contractures after burn: A systematic review. Burns. 2016; 43(1):41-49. DOI: 10.1016/j.burns.2016.08.002. View

4.
De Felice B, Garbi C, Santoriello M, Santillo A, Wilson R . Differential apoptosis markers in human keloids and hypertrophic scars fibroblasts. Mol Cell Biochem. 2009; 327(1-2):191-201. DOI: 10.1007/s11010-009-0057-x. View

5.
Li M, Xu J, Shi T, Yu H, Bi J, Chen G . Epigallocatechin-3-gallate augments therapeutic effects of mesenchymal stem cells in skin wound healing. Clin Exp Pharmacol Physiol. 2016; 43(11):1115-1124. DOI: 10.1111/1440-1681.12652. View